161 related articles for article (PubMed ID: 17482465)
21. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population.
Tice JA; Miike R; Adduci K; Petrakis NL; King E; Wrensch MR
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):324-8. PubMed ID: 15734953
[TBL] [Abstract][Full Text] [Related]
22. Cytomorphology as a risk predictor: experience with fine needle aspiration biopsy, nipple fluid aspiration, and ductal lavage.
Masood S
Clin Lab Med; 2005 Dec; 25(4):827-43, viii-ix. PubMed ID: 16308095
[TBL] [Abstract][Full Text] [Related]
23. Chemoprevention in postmenopausal women.
Rastogi P
Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
[TBL] [Abstract][Full Text] [Related]
24. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
25. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer.
Varnum SM; Covington CC; Woodbury RL; Petritis K; Kangas LJ; Abdullah MS; Pounds JG; Smith RD; Zangar RC
Breast Cancer Res Treat; 2003 Jul; 80(1):87-97. PubMed ID: 12889602
[TBL] [Abstract][Full Text] [Related]
26. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
27. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk.
Sauter ER; Lininger J; Magklara A; Hewett JE; Diamandis EP
Int J Cancer; 2004 Feb; 108(4):588-91. PubMed ID: 14696124
[TBL] [Abstract][Full Text] [Related]
28. Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings.
Sauter ER; Wagner-Mann C; Ehya H; Klein-Szanto A
Cancer Detect Prev; 2007; 31(1):50-8. PubMed ID: 17317033
[TBL] [Abstract][Full Text] [Related]
29. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery.
Kuerer HM; Goldknopf IL; Fritsche H; Krishnamurthy S; Sheta EA; Hunt KK
Cancer; 2002 Dec; 95(11):2276-82. PubMed ID: 12436432
[TBL] [Abstract][Full Text] [Related]
30. Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months.
Frank DH; Kimler BF; Fabian CJ; Ranger-Moore J; Yozwiak M; Bartels HG; Alberts DS; Bartels PH
Breast Cancer Res Treat; 2009 Jun; 115(3):661-8. PubMed ID: 19125322
[TBL] [Abstract][Full Text] [Related]
31. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
[TBL] [Abstract][Full Text] [Related]
32. The future of the new selective estrogen receptor modulators.
Palacios S
Menopause Int; 2007 Mar; 13(1):27-34. PubMed ID: 17448265
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen (PSA) in women.
Yu H; Berkel H
J La State Med Soc; 1999 Apr; 151(4):209-13. PubMed ID: 10234897
[TBL] [Abstract][Full Text] [Related]
34. uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.
Qin W; Zhu W; Hewett JE; Rottinghaus G; Chen YC; Flynn JT; Kliethermes B; Mannello F; Sauter ER
BMC Cancer; 2008 Oct; 8():298. PubMed ID: 18922176
[TBL] [Abstract][Full Text] [Related]
35. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
36. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials.
Arun B; Valero V; Logan C; Broglio K; Rivera E; Brewster A; Yin G; Green M; Kuerer H; Gong Y; Browne D; Hortobagyi GN; Sneige N
Clin Cancer Res; 2007 Aug; 13(16):4943-8. PubMed ID: 17699874
[TBL] [Abstract][Full Text] [Related]
37. Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.
Saji S; Kuroi K
Breast Cancer; 2008; 15(4):262-9. PubMed ID: 18654829
[TBL] [Abstract][Full Text] [Related]
38. 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Akashi-Tanaka S; Shimizu C; Ando M; Shibata T; Katsumata N; Kouno T; Terada K; Shien T; Yoshida M; Hojo T; Kinoshita T; Fujiwara Y; Yoshimura K
Breast; 2009 Jun; 18(3):171-4. PubMed ID: 19410462
[TBL] [Abstract][Full Text] [Related]
39. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
40. Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry.
He J; Gornbein J; Shen D; Lu M; Rovai LE; Shau H; Katz J; Whitelegge JP; Faull KF; Chang HR
Int J Oncol; 2007 Jan; 30(1):145-54. PubMed ID: 17143523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
